Retraction Note: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin (Leukemia, (2008), 22, 7, (1402-1409), 10.1038/leu.2008.89);Disruption of the Bcr-Abl/Hsp90 protein complex: A possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin

Leukemia

Volumn 22, Issue 7, 2008, Pages 1402-1409

  Wu, L X ^a   Xu, J H ^a   Zhang, K Z ^a   Lin, Q ^a   Huang, X W ^a   Wen, C X ^a   Chen, Y Z ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CASPASE 9; CYTOCHROME C; HEAT SHOCK PROTEIN 90; N ACETYLLEUCYLLEUCYLNORLEUCINAL; NOVOBIOCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN HL 60; CELL STRAIN K 562; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOSOL; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION;

APOPTOSIS; BENZOQUINONES; BLAST CRISIS; CASPASE 3; CASPASE 9; CELL PROLIFERATION; CYTOCHROMES C; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; K562 CELLS; LACTAMS, MACROCYCLIC; LEUKEMIA; NOVOBIOCIN; PIPERAZINES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRIMIDINES;

EID: 47549091775     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/s41375-020-0823-z     Document Type: Erratum

References (28)

1. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995; 11: 933-939.
2. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J et al p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/ GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 1996; 271: 4974-4977.
3. Stepanova L, Leng X, Parker SB, Harper JW. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491-1502.
4. Scheibel T, Neuhofen S, Weikl T, Mayr C, Reinstein J, Vogel PD et al ATP-binding properties of human Hsp90. J Biol Chem 1997; 272: 18608-18613.
5. Scheibel T, Weikl T, Buchner J. Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence. Proc Natl Acad Sci USA 1998; 95: 1495-1499.
6. Grenert JP, Sullivan WP, Fadden P, Haystead TAJ, Clark J, Mimnaugh E et al. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997; 272: 23843-23850.
7. Grenert JP, Johnson BD, Toft DO. The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. J Biol Chem 1999; 274: 17525-17533.
8. Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 2000; 92: 242-248.
9. Allan RK, Mok D, Ward BK, Ratajczak T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: Evidence that coumarin antibiotics disrupt Hsp90 dimerization. J Biol Chem 2006; 281: 7161-7171.
10. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia. Biology and therapy. Ann Intern Med 1999; 131: 207-219.
11. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: A unique therapeutic opportunity. Mol Cancer Ther 2004; 3: 1021-1030.
12. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61: 1799-1804.
13. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
14. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphi-achromosome-positive leukaemia to STI571: A prospective study. Lancet 2002; 359: 487-491.
15. Qi J, Peng H, Gu ZL, Liang ZQ, Yang CZ. Establishment of an imatinib resistant cell line K562/G01 and its characterization. Chin J Hematol 2004; 25: 337-341.
16. Bhatia R, McGlave PB, Miller JS, Wissink S, Lin WN, Verfaillie CM. A clinical lysuitable ex vivo expansion culture system for LTC-IC and CFC using stroma-conditioned medium. Exp Hematol 1997; 25 980-991.
17. Bhatia R, McGlave PB, Dewald GW, Blazar BR, Verfaillie CM. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages. Blood 1995; 85 3636-3645.
18. Jow GM, Chou CJ, Chen BF, Tsai JH. Beauvericin induces cytotoxic effects in human acute lymphoblastic leukemia cells through cytochrome c release, caspase 3 activation: The causative role of calcium. Cancer Lett 2004; 216: 165-173.
19. Wu LX, Xu JH, Huang XW, Zhang KZ, Wen CX, Chen YZ. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90. Acta Pharmacol Sin 2006; 27: 694-699.
20. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and Bid proteins in etoposide-or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000; 60: 1645-1653.
21. King MA. Detection of dead cells and measurement of cell killing by flow cytometry. J Immunol Methods 2000; 243: 155-166.
22. Amarante-Mendes G, Kim C, Liu L, Huang Y, Perkins C, Green D et al Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 1998; 91: 1700-1705.
23. Guo F, Rocha K, Bali P, Pranpat M, Fiskus W, Boyapalle S et al. Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res 2005; 65: 10536-10544.
24. Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005; 105: 1246-1255.
25. Johnson BD, Schumacher RJ, Ross ED, Toft DO. Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem 1998; 273: 3679-3686.
26. Chen S, Prapapanich V, Rimerman RA, Honore B, Smith DF. Interactions of p60, a mediator of progesterone receptor assembly, with heat shock proteins hsp90 and hsp70. Mol Endocrinol 1996; 10: 682-693.
27. Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother 1986; 30: 42-45.
28. Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BSJ. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. J Am Chem Soc 2006; 128: 15529-15536.